Claude Fable, the company's most powerful model, is now available to all users, but early impressions are disappointing, as ...

Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early ...